EX-99.3 4 brhc10013829_99-3.htm EXHIBIT 99.3 Exhibit 99.3


InflaRx Reports Q2 2020 Financial & Operating Results

•
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate
•
Completed end-of-Phase II meeting with the FDA for IFX-1 in hidradenitis suppurativa
•
Received positive EMA scientific advice suggesting that IHS4 could be used as primary endpoint in InflaRx´s pivotal development in hidradenitis suppurativa
•
Cash, cash equivalents and financial assets of approximately €98.9 million as of June 30, 2020

Jena, Germany, 30 July 2020 – InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three and six months ended June 30, 2020.

“The encouraging data from the randomized exploratory first part of our study in COVID-19 are in line with the mode of action of IFX-1 and give hope that C5a inhibition with IFX-1 may be a life-saving treatment option. The results have been submitted for publication in a peer-reviewed medical journal and to a pre-print server, and we are planning an adequately controlled and powered Phase III part of the study in critically ill COVID-19 patients,” said Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx.

Prof. Riedemann continued, “We just received the EMA scientific advice agreeing with our arguments on the limitations of the currently used score in hidradenitis suppurativa development (HiSCR) and suggesting that IHS4 could be used as the primary endpoint in our pivotal studies. Our initial interactions with both EMA and FDA related to a Phase III development program in hidradenitis suppurativa have shown us that IFX-1 is a Phase III ready drug candidate. We are working on a strategy to address the FDA´s concerns related to the suggested change in the primary endpoint and plan additional FDA interactions on this topic. Our other clinical programs with IFX-1 are moving forward in pyoderma gangraenosum and ANCA-associated vasculitis. Depending on the COVID-19 situation, we expect readouts in these indications in 2021.”


Recent R&D Highlights

•
IFX-1 in COVID-19 induced pneumonia: In June 2020, InflaRx announced encouraging results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 induced pneumonia.  Positive treatment trends were seen in the 28-day all-cause mortality rate and in various other endpoints.  Twenty-eight-day all-cause mortality in the IFX-1 treatment group was 13% (2 out of 15) versus 27% (4 out of 15) in the control group. In the best supportive care group, four patients died of COVID-19-induced multi-organ failure, and three of them had pulmonary embolisms reported as a serious adverse event. In the IFX-1 treatment arm, one patient died after an acute ventilator tube complication (leakage) leading to hypoxia, and one patient who met an exclusion criterion with a history of severe chronic obstructive pulmonary disease, which was not known at time point of enrollment, died of pulmonary failure.  Additionally, fewer patients in the IFX-1 treatment arm experienced renal impairment assessed by estimated glomerular filtration rates, and more patients showed reversal of blood lymphocytopenia and a greater lowering of lactate dehydrogenase concentrations as a sign of reduction in tissue damage. A temporary significant increase of D-dimer levels in the first days following IFX-1 administration was noted, as potentially an expression of induction of blood clot lysis. No statistically significant group differences on the chosen primary endpoint of relative change (%) from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) were detected. However, the exploratory first part of this study was not powered to show such differences. InflaRx is now planning an adequately powered, placebo-controlled, double blinded Phase III part using 28-day all-cause mortality as the primary endpoint, an accepted regulatory primary endpoint for critical care studies.

•
IFX-1 in Hidradenitis Suppurativa (HS): In June 2020, InflaRx completed an end-of-Phase II meeting with the FDA to discuss a Phase III program for the use of IFX-1 for the treatment of HS. The FDA agreed to key proposals to support a Biologics License Application (BLA) submission, including aspects of the Phase III trial design, IFX-1 dosing, target study population, and the nonclinical and clinical pharmacology packages. While the FDA did not agree that the International Hidradenitis Suppurativa Severity Score (“IHS4”) is fit for purpose as a primary efficacy endpoint tool to support labeling, the FDA recommended that the Company obtain HS patient input to help determine the validity of the IHS4 score. The Company is now assessing different strategies for a potential pathway to regulatory approval for IFX-1 in the United States and plans to engage with the FDA on next steps.

 
Additionally, the Company requested scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval and received feedback in July 2020. Although the EMA noted certain considerations regarding the Company’s proposal, the EMA acknowledged that HiSCR response does not account for the clinical relevance of a reduction in draining fistulas and the effort to construct a new endpoint that better captures these changes was endorsed in principle.  According to the EMA, although HiSCR was used as an endpoint in previous studies, IHS4 could be an appropriate tool to evaluate the efficacy of a novel compound in HS. The Company is working diligently to address the additional feedback received and analyzing the strategy for its Phase III development in HS.

•
IFX-1 in Pyoderma Gangraenosum (PG): The Phase IIa open label trial continues to enroll patients in the higher dose groups. Additional clinical trial sites continue to be opened to support enrollment. Results from the higher dose groups are expected in 2021.

•
IFX-1 in ANCA-associated vasculitis (AAV): In the European Phase II IXCHANGE trial, Part 2 continues to enroll patients.  Final results are expected in 2021.

•
IFX-1 in oncology: Activities are ongoing for the Phase IIa oncology program, with expected initiation in the first half of 2021.

Financial highlights – H1 2020

Research and development expenses incurred for the six months ended June 30, 2020

decreased over the corresponding period in 2019 by €5.5 million. This decline was primarily due to lower contribution of expense in the period from the Phase IIb clinical development of IFX-1 in HS since this study was completed in 2019, offset by the COVID-19 trial expenses. These two factors led to a net decline of €3.7 million in third-party expenses. Furthermore third-party manufacturing expenses also declined by €1.0 million. Additionally, equity-settled share-based compensation recognized in personnel expenses decreased by €0.9 million.

General and administrative expenses decreased by €2.1 million to €4.9 million for the six months ended June 30, 2020, from €6.9 million for the six months ended June 30, 2019. This decrease is primarily attributable to decreasing expenses associated with equity-settled share-based compensation recognized in personnel expenses (€1.5 million). Furthermore, legal, consulting and other expenses decreased by €0.7 million to €2.1 million for the six months ended June 30, 2020, from €2.8 million for the six months ended June 30, 2019. In 2019, consulting costs were higher due to a onetime strategic project.

 
Net financial result decreased by €1.0 million to €1.1 million for the six months ended June 30, 2020, from €2.0 million for the six months ended June 30, 2019. This decrease is mainly attributable to lower interest earned on marketable securities (€1.1 million), partially offset by a higher foreign exchange result (higher gains €0.9 million and €0.5 million higher losses).

Net loss for the six months ended June 30, 2020 was €18.3 million or €(0.70) per common share, compared to €25.1 million or €(0.97) per common share for the six months ended June 30, 2019. On June 30, 2020, the Company’s total funds available were approximately €98.9 million, composed of cash and cash equivalents (€36.4 million) and financial assets (€62.5 million).

Net cash used in operating activities decreased to €18.2 million in the six months ended June 30, 2020, from €18.7 million in the six months ended June 30, 2019, mainly due to the decrease of cash expenses, such as third-party expenses for manufacturing and clinical trials for our lead program IFX-1, compensated by lower payments on trade liabilities in the six months ended June 30, 2019.

Additional information regarding these results and other relevant information is included in the notes to the unaudited Condensed Consolidated Financial Statements as of June 30, 2020, as well as the financial statements as of December 31, 2019 in “ITEM 18. Financial statements,” which is included in InflaRx’s Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission (SEC).

 
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Operations and
Comprehensive Loss for the three and six months ended June 30, 2020 and 2019

 
   
For the three months ended
June 30,
    
For the six months ended
June 30,
  
(in €, except for share data)
  
2020
(unaudited)
    
2019
(unaudited)
    
2020
(unaudited)
    
2019
(unaudited)
  
                         
Operating Expenses
                        
Research and development expenses
    
(7,356,326
)
    
(12,497,222
)
    
(14,655,125
)
    
(20,192,372
)
General and administrative expenses
    
(2,326,895
)
    
(3,647,849
)
    
(4,891,698
)
    
(6,949,015
)
Total Operating Expenses
    
(9,683,221
)
    
(16,145,071
)
    
(19,546,822
)
    
(27,141,387
)
Other income
    
102,332
      
2,866
      
197,292
      
67,702
  
Other expenses
    
(3,450
)
    
(79,183
)
    
(9,170
)
    
(83,068
)
Operating Result
    
(9,584,339
)
    
(16,221,387
)
    
(19,358,701
)
    
(27,156,753
)
Finance income
    
609,444
      
1,338,755
      
2,268,436
      
2,497,960
  
Finance expenses
    
(1,057,937
)
    
(388,097
)
    
(1,175,964
)
    
(449,807
)
Net Financial Result
    
(448,493
)
    
950,659
      
1,092,472
      
2,048,153
  
Loss for the Period
    
(10,032,832
)
    
(15,270,729
)
    
(18,266,229
)
    
(25,108,600
)
                                 
Share Information
                                
Weighted average number of shares outstanding
    
26,172,023
      
25,964,379
      
26,138,639
      
25,964,379
  
Loss per share (basic/diluted)
    
(0.38
)
    
(0.59
)
    
(0.70
)
    
(0.97
)
                                 
Loss for the Period
    
(10,032,832
)
    
(15,270,729
)
    
(18,266,229
)
    
(25,108,600
)
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:
                                
Exchange differences on translation of foreign currency
    
(1,452,973
)
    
(1,622,079
)
    
260,895
      
695,468
  
Total Comprehensive Loss
    
(11,485,805
)
    
(16,892,807
)
    
(18,005,334
)
    
(24,413,132
)

 
InflaRx N.V. and subsidiary
Unaudited Condensed Consolidated Statements of Financial Position
as of June 30, 2020 and December 31, 2019

in €
  
June 30,
2020
(unaudited)
    
December 31,
2019
  
             
ASSETS
            
Non-current assets
            
Property, plant and equipment
    
493,377
      
576,373
  
Right-of-use assets
    
716,871
      
836,924
  
Intangible assets
    
404,251
      
452,400
  
Other assets
    
419,424
      
452,217
  
Financial assets
    
272,627
      
272,614
  
Total non-current assets
    
2,306,550
      
2,590,528
  
Current assets
                
Other assets
    
2,973,228
      
3,500,884
  
Financial assets
    
62,191,912
      
82,353,867
  
Cash and cash equivalents
    
36,398,578
      
33,131,280
  
Total current assets
    
101,563,718
      
118,986,031
  
TOTAL ASSETS
    
103,870,268
      
121,576,558
  
                 
EQUITY AND LIABILITIES
                
Equity
                
Issued capital
    
3,152,427
      
3,132,631
  
Share premium
    
211,483,756
      
211,006,606
  
Other capital reserves
    
26,627,185
      
25,142,213
  
Accumulated deficit
    
(152,628,234
)
    
(134,362,006
)
Other components of equity
    
2,488,124
      
2,227,228
  
Total equity
    
91,123,258
      
107,146,673
  
Non-current liabilities
                
Lease liabilities
    
203,636
      
330,745
  
Other non-financial liabilities
    
37,644
      
39,013
  
Total non-current liabilities
    
241,280
      
369,758
  
Current liabilities
                
Trade and other payables
    
10,630,462
      
12,413,662
  
Lease liabilities
    
524,034
      
515,203
  
Employee benefits
    
867,121
      
975,629
  
Social security, other tax and non-financial liabilities
    
448,113
      
105,634
  
Provisions
    
36,000
      
50,000
  
Total current liabilities
    
12,505,730
      
14,060,128
  
Total Liabilities
    
12,747,010
      
14,429,886
  
TOTAL EQUITY AND LIABILITIES
    
103,870,268
      
121,576,558
  

 
InflaRx N.V. and subsidiary
Unaudited Condensed Consolidated Statements of Changes in Shareholders’
Equity for the six months ended June 30, 2020 and 2019

(in €, except for share data)
  
Issued
capital
    
Share
premium
    
Other
capital
reserves
    
Accumulated
deficit
    
Other
components of
equity
    
Total
equity
  
                                     
Balance as of January 1, 2020
    
3,132,631
      
211,006,606
      
25,142,213
      
(134,362,006
)
    
2,227,228
      
107,146,673
  
Loss for the period
    
—
      
—
      
—
      
(18,266,229
)
    
—
      
(18,266,229
)
Exchange differences on translation of foreign currency
    
—
      
—
      
—
      
—
      
260,895
      
260,895
  
Total comprehensive loss
    
—
      
—
      
—
      
(18,266,229
)
    
260,895
      
(18,005,334
)
Contributions
                                                
Equity-settled share-based payment
    
—
      
—
      
1,484,972
      
—
      
—
      
1,484,972
  
Share options exercised
    
19,797
      
477,149
      
—
      
—
      
—
      
496,946
  
Total Contributions
    
19,797
      
477,149
      
1,484,972
      
—
      
—
      
1,981,918
  
Balance as of June 30, 2020
    
3,152,427
      
211,483,756
      
26,627,185
      
(152,628,234
)
    
2,488,124
      
91,123,258
  
                                                 
Balance as of January 1, 2019
    
3,115,725
      
211,021,835
      
18,310,003
      
(81,107,188
)
    
50,196
      
151,390,571
  
Loss for the period
    
—
      
—
      
—
      
(25,108,600
)
    
—
      
(25,108,600
)
Exchange differences on translation of foreign currency
    
—
      
—
      
—
      
—
      
695,468
      
695,468
  
Total comprehensive loss
    
—
      
—
      
—
      
(25,108,600
)
    
695,468
      
(24,413,132
)
Contributions
                                                
Equity-settled share-based payment
    
—
      
—
      
3,889,767
      
—
      
—
      
3,889,767
  
Total Contributions
    
—
      
—
      
3,889,767
      
—
      
—
      
3,889,767
  
Balance as of June 30, 2019
    
3,115,725
      
211,021,835
      
22,199,770
      
(106,215,788
)
    
745,663
      
130,867,206
  
                                                 

 
InflaRx N.V. and subsidiary
Unaudited Condensed Consolidated Statements of Cash Flows
for the six months ended June 30, 2020 and 2019

in €
  
For the six months ended June 30, 2020
(unaudited)
    
For the six months ended June 30, 2019
(unaudited)
  
             
Operating activities
            
Loss for the period
    
(18,266,229
)
    
(25,108,600
)
Adjustments for:
                
Depreciation & amortization of property, plant, equipment, right-of-use assets and intangible assets
    
353,976
      
307,130
  
Net financial result
    
(1,092,472
)
    
(2,048,153
)
Share-based payment expense
    
1,484,972
      
3,889,767
  
Net foreign exchange differences
    
(789,528
)
    
(205,103
)
Changes in:
                
Other assets
    
560,449
      
(2,063,491
)
Employee benefits
    
(122,411
)
    
(84,890
)
Social security and other current non-financial liabilities
    
341,012
      
(184,120
)
Trade and other payables
    
(1,783,200
)
    
5,513,355
  
Interest received
    
1,096,651
      
1,269,745
  
Interest paid
    
(5,455
)
    
(16,308
)
Net cash used in operating activities
    
(18,222,235
)
    
(18,730,669
)
Investing activities
                
Purchase of intangible assets, laboratory and office equipment
    
(35,107
)
    
(503,881
)
Purchase of non-current other financial assets
    
—
      
(75,543
)
Disposal of non-current other financial assets
    
—
      
3,088
  
Purchase of current financial assets
    
(59,196,096
)
    
—
  
Proceeds from the maturity of financial assets
    
56,553,296
      
17,709,459
  
Net cash from investing activities
    
20,272,857
      
17,133,122
  
Financing activities
                
Proceeds from exercise of share options
    
496,946
      
—
  
Repayment of lease liabilities
    
(183,970
)
    
(125,075
)
Net cash from/ (used in) financing activities
    
312,976
      
(125,075
)
Net (decrease)/increase in cash and cash equivalents
    
2,363,597
      
(1,722,622
)
Effect of exchange rate changes on cash and cash equivalents
    
903,700
      
399,266
  
Cash and cash equivalents at beginning of period
    
33,131,280
      
55,386,240
  
Cash and cash equivalents at end of period
    
36,398,578
      
54,062,885
  

 
About IFX-1:

IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and COVID-19 pneumonia.

About InflaRx N.V.:

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com.

Contacts:

InflaRx N.V.

Jordan Zwick – Global Head of Business Development & Corporate Strategy
Email: jordan.zwick[at]inflarx.de
Tel: +1 917-338-6523

MC Services AG

Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx[at]mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752

 
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing  of and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.